Skip to main content
CivicGate

HR 679
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

Introduced Jan 23, 2025

Latest action (Jan 23, 2025) Referred to the House Committee on Energy and Commerce.

Referred to
Energy and Commerce Committee
Policy area
Health
Issues
AbortionHealthcare
Legislative subjects (4)
AbortionDrug safety, medical device, and laboratory regulationDrug therapyPrescription drugs

Summary

The bill nullifies modifications that the Food and Drug Administration made in January 2023 to the risk evaluation and mitigation strategy for mifepristone. It also prohibits the Secretary of Health and Human Services from establishing, implementing, or enforcing any substantially similar provisions to the nullified modifications regarding the risk evaluation and mitigation strategy for mifepristone.

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)
18 cosponsors

Actions (2)
  1. Jan 23, 2025 Referred to the House Committee on Energy and Commerce. · house
  2. Jan 23, 2025 Introduced in House

More bills on these subjects (8)

Other bills that carry the most legislative subjects in common with this one (topical discovery — distinct from the procedural related bills above).

  • HR 1525 — Protecting Life from Chemical Abortions Act (shares 4 subjects)
  • HR 9770 — Continuing Appropriations Act, 2027 (shares 3 subjects)
  • S 2882 — Continuing Appropriations and Extensions and Other Matters Act, 2026 (shares 3 subjects)
  • HR 5450 — Continuing Appropriations and Extensions and Other Matters Act, 2026 (shares 3 subjects)
  • HR 1968 — Full-Year Continuing Appropriations and Extensions Act, 2025 (shares 3 subjects)
  • HR 1349 — Women’s Protection in Telehealth Act (shares 3 subjects)
  • HR 685 — SAVE Moms and Babies Act of 2025 (shares 3 subjects)
  • HR 629 — Ending Chemical Abortions Act of 2025 (shares 3 subjects)

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

  • HRES 803 — Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes. · Introduced Oct 10, 2025 · Cong. 119 78%
  • S 1631 — Restoring Safeguards for Dangerous Abortion Drugs Act · Introduced May 6, 2025 · Cong. 119 74%
  • HR 7902 — Safeguarding Women from Chemical Abortion Act · Introduced Mar 12, 2026 · Cong. 119 72%
  • S 4066 — Safeguarding Women from Chemical Abortion Act · Introduced Mar 11, 2026 · Cong. 119 71%
  • SRES 732 — A resolution expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science. · Introduced May 14, 2026 · Cong. 119 69%
  • HRES 1285 — Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science. · Introduced May 14, 2026 · Cong. 119 69%

Full text

IN THE HOUSE OF REPRESENTATIVES

January 23, 2025

Mrs. Harshbarger (for herself, Mr. Hern of Oklahoma, Mr. Bost, Mrs. Miller of Illinois, Mr. Weber of Texas, Mr. Babin, Mr. Moolenaar, Mr. Webster of Florida, Mr. Baird, Mr. Higgins of Louisiana, Mr. Feenstra, Mr. Yakym, Mr. Biggs of Arizona, Mr. Palmer, and Mr. Guest) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. NULLIFICATION OF MODIFICATIONS TO REMS FOR MIFEPRISTONE.

(a) Nullification.—The modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone are hereby nullified.

(b) No Substantially Similar Provisions.—The Secretary of Health and Human Services (or any head of any office, department, or agency of the Department of Health and Human Services) shall not establish, implement, or enforce any provision of a risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone that is substantially similar to any of the modifications nullified by subsection (a). <all>

Comments

Comments

Loading comments…